| Literature DB >> 26290869 |
Cheng-Kuan Lin1, Yu-Ying Chang2, Jung-Der Wang3, Lukas Jyuhn-Hsiarn Lee4.
Abstract
OBJECTIVE: This paper aimed to determine the standardised incidence ratio (SIR) of malignant pleural mesothelioma (MPM) in workers exposed to asbestos in Taiwan.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26290869 PMCID: PMC4531167 DOI: 10.1155/2015/678598
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic characteristics of the cohort, 1950–2009.
| Case number (%) | |||
|---|---|---|---|
| Total | Male | Female | |
| 160640 | 121883 (75.9) | 38757 (24.1) | |
| Asbestos-related industry | |||
| Asbestos cement industry | 5919 (3.68) | 4965 (4.07) | 954 (2.46) |
| Asbestos friction industry | 10681 (6.65) | 6745 (5.53) | 3936 (10.16) |
| Asbestos thermal insulation industry | 3554 (2.21) | 2477 (2.03) | 1077 (2.78) |
| Industries using serpentine | 10261 (6.39) | 7089 (5.82) | 3172 (8.18) |
| Those applications with use | 13220 (8.23) | 9630 (7.9) | 3590 (9.26) |
| Those applications without use | 19488 (12.13) | 11640 (9.55) | 7848 (20.25) |
| Not classified | 97517 (60.71) | 79337 (65.09) | 18180 (46.91) |
| Period of first employment | |||
| 1950~1979 | 70399 (43.82) | 58080 (47.65) | 12319 (31.79) |
| 1980~2009 | 90241 (56.18) | 63803 (52.35) | 26438 (68.21) |
| Duration of employment (year) | |||
| <1 | 78999 (49.18) | 59918 (49.16) | 19081 (49.23) |
| 1–9 | 60074 (37.4) | 44658 (36.64) | 15416 (39.78) |
| 10–19 | 11572 (7.2) | 9137 (7.5) | 2435 (6.28) |
| ≥20 | 9995 (6.22) | 8170 (6.7) | 1825 (4.71) |
| First exposure age (years old) | |||
| <30 | 113202 (70.47) | 86025 (70.58) | 27177 (70.12) |
| 30–39 | 28234 (17.58) | 20757 (17.03) | 7477 (19.29) |
| ≥40 | 19204 (11.95) | 15101 (12.39) | 4103 (10.59) |
Observed and expected numbers and standardized incidence ratios for cancers among the male and female workers employed in asbestos-related factories.
| Cancer type | Males | Females | ||||
|---|---|---|---|---|---|---|
| Obs. N.O. | Exp. N.O. | SIR | Obs. N.O. | Exp. N.O. | SIR | |
| All cancers | 6544 | 13731.1 | 0.48 | 1894 | 2357.8 | 0.80 |
| Lip, oral cavity, and pharynx | 726 | 1206.1 | 0.60 | 20 | 27.62 | 0.72 (0.44–1.12) |
| Major salivary glands | 26 | 29.58 | 0.88 (0.57–1.29) | 6 | 5.79 | 1.04 (0.38–2.25) |
| Nasopharynx | 363 | 439.58 | 0.83 | 43 | 39.62 | 1.09 (0.79–1.46) |
| Esophagus | 241 | 378.2 | 0.64 | 5 | 5.62 | 0.89 (0.29–2.08) |
| Stomach | 409 | 591.48 | 0.69 | 58 | 76.96 | 0.75 |
| Colon, rectum, and anus | 872 | 5186.73 | 0.17 | 147 | 623.28 | 0.24 |
| Liver and intrahepatic bile ducts | 1280 | 1971.02 | 0.65 | 120 | 143.87 | 0.83 |
| Gall bladder and extrahepatic bile ducts | 45 | 87.53 | 0.51 | 9 | 16.64 | 0.54 (0.25–1.03) |
| Pancreas | 104 | 167.71 | 0.62 | 19 | 23.64 | 0.80 (0.48–1.25) |
| Nose, middle ear, and sinuses | 18 | 34.84 | 0.52 | 1 | 4.14 | 0.24 (0.01–1.35) |
| Larynx | 86 | 139.96 | 0.61 | 3 | 1.77 | 1.69 (0.35–4.95) |
| Trachea, bronchus, and lung | 758 | 1222.97 | 0.62 | 123 | 144.80 | 0.85 (0.71–1.01) |
| Retroperitoneum | 6 | 13.99 | 0.43 | 4 | 3.95 | 1.01 (0.28–2.60) |
| Pleura (malignant mesothelioma) | 17 | 6.41 | 2.65 | 1 | 0.60 | 1.67 (0.04–9.29) |
| Bone and articular cartilage | 15 | 19.54 | 0.77 (0.43–1.27) | 2 | 4.41 | 0.45 (0.05–1.64) |
| Skin | 205 | 249.04 | 0.82** (0.71–0.94) | 43 | 44.04 | 0.98 (0.71–1.32) |
| Female breast | — | — | — | 494 | 493.63 | 1.00 (0.91–1.09) |
| Uterus and corpus uteri | — | — | — | 78 | 73.51 | 1.06 (0.84–1.32) |
| Cervix | — | — | — | 412 | 238.08 | 1.73** (1.57–1.91) |
| Adnexa (including ovary) | — | — | — | 53 | 67.28 | 0.79 (0.59–1.03) |
| Prostate | 307 | 459.99 | 0.67** (0.59–0.75) | — | — | — |
| Bladder | 234 | 310.72 | 0.75** (0.66–0.86) | 19 | 26.25 | 0.72 (0.44–1.13) |
| Kidney | 96 | 118.19 | 0.81* (0.66–0.99) | 11 | 26.77 | 0.41** (0.20–0.74) |
| Renal pelvis and ureter | 80 | 114.29 | 0.70** (0.56–0.87) | 21 | 14.77 | 1.42 (0.88–2.17) |
| Brain | 60 | 86.82 | 0.69** (0.53–0.89) | 15 | 16.10 | 0.93 (0.52–1.54) |
| Thyroid gland | 76 | 91.61 | 0.83 (0.65–1.04) | 91 | 88.98 | 1.02 (0.82–1.26) |
| Hodgkin lymphoma | 146 | 233.45 | 0.63** (0.53–0.74) | 3 | 2.27 | 1.32 (0.27–3.87) |
| Non-Hodgkin lymphoma | 6 | 12.96 | 0.46 (0.17–1.01) | 27 | 41.66 | 0.65* (0.43–0.94) |
| Leukemia | 118 | 165.06 | 0.71** (0.59–0.86) | 22 | 30.13 | 0.73 (0.46–1.11) |
| Others | 250 | 393.35 | 0.64** (0.56–0.72) | 44 | 71.68 | 0.61** (0.45–0.82) |
P < 0.01, P < 0.05. Obs. N.O.: observed number. Exp. N.O.: expected number; 95% CI: 95% confidence interval.
Observed and expected numbers and the SIR with the 95% CI for malignant pleural mesothelioma among the male workers employed in asbestos-related factories, by period of first employment in the factory and time since first employment: follow-up for 1980–2009.
| Period of first employment | Time since first employment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10–20 years | 20–30 years | >30 years | Total | |||||||||
| Obs. ( | Exp. ( | SIR (95% CI) | Obs. ( | Exp. | SIR (95% CI) | Obs. ( | Exp. ( | SIR (95% CI) | Obs. ( | Exp. ( | SIR (95% CI) | |
| 1950–1979 | 0 | 0.45 | 0.00 (0.00–8.12) | 5 | 1.37 | 3.65 | 11 | 2.43 | 4.52 | 16 | 4.35 | 3.68 |
| 1980–1989 | 0 | 0.54 | 0.00 (0.00–6.79) | 1 | 0.79 | 1.26 (0.03–7.03) | 0 | 0.05 | 0.00 (0.00–70.78) | 1 | 1.6 | 0.62 (0.00–3.48) |
|
| ||||||||||||
| Total period | 0 | 1 | 0.00 (0.00–3.70) | 6 | 2.16 | 2.78 | 11 | 2.48 | 4.43 | 17 | 5.95 | 2.86 |
P < 0.01, P < 0.05. Obs. (N): observed numbers. Exp. (N): expected numbers; SIR: standardized incidence ratio; 95% CI: 95% confidence interval.
Observed and expected numbers and the SIR with the 95% CI for malignant pleural mesothelioma among the male workers employed in asbestos-related factories, by duration of employment in the factory and time since first employment: follow-up for 1980–2009.
| Duration of employment | Time since first employment | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10–20 years | 20–30 years | >30 years | Total | ||||||||||
| Obs. ( | Exp. ( | SIR (95% CI) | Obs. ( | Exp. ( | SIR (95% CI) | Obs. ( | Exp. ( | SIR (95% CI) | Obs. ( | Exp. ( | SIR (95% CI) | ||
| <1 year | 0 | 0.49 | 0.00 (0.00–7.45) | 4 | 1.0446 | 3.83 | 3 | 0.9784 | 3.07 (0.63–8.96) | 7 | 2.678 | 2.61 | |
| 1–10 years | 0 | 0.37 | 0.00 (0.00–9.85) | 1 | 0.7856 | 1.27 (0.03–7.09) | 5 | 0.9531 | 5.25 | 6 | 2.2586 | 2.66 (0.97–5.78) | |
| 11–20 years | 0 | 0.13 | 0.00 (0.00–28.64) | 0 | 0.1695 | 0.00 (0.00–21.76) | 1 | 0.196 | 5.10 (0.13–28.42) | 1 | 0.4943 | 2.02 (0.05–11.27) | |
| >20 years | 0 | 0.00 | 0.00 − 1.5 × 108 | 1 | 0.1623 | 6.16 (0.16–34.34) | 2 | 0.3569 | 5.60 (0.68–20.24) | 3 | 0.5192 | 5.78 | |
|
| |||||||||||||
| Total | 0 | 1.00 | 0.00 (0.00–3.70) | 6 | 2.162 | 2.78 | 11 | 2.4845 | 4.43 | 17 | 5.9501 | 2.86 | |
P < 0.01, P < 0.05. Obs. (N): observed numbers. Exp. (N): expected numbers; SIR: standardized incidence ratio; 95% CI: 95% confidence interval.
Characteristics of 17 male cases of MPM employed in asbestos-related factories.
| Characteristics | Percentage (%) |
|---|---|
| Histology (ICD-O) | |
| Mesothelioma, malignant, NOS (9050/3) | 64.7 |
| Fibrous mesothelioma, malignant (9051/3) | 11.8 |
| Epithelioid mesothelioma, malignant (9052/3) | 23.5 |
| Period of cancer diagnosis | |
| 1980–1999 | 11.8 |
| 2000–2009 | 88.2 |
|
| |
| Other characteristics | Median (range), years |
|
| |
| Age at first employment | 25 (15–48) |
| Age at cancer diagnosis | 63 (38–74) |
| Latency (time since first employment to cancer diagnosis) | 33.2 (22.7–56.4) |
| Duration of employment | 1.7 (0.1–30) |
Coded by International Classification of Diseases for Oncology- (ICD-O-) 3rd ed., published by WHO Library Cataloguing-in-Publication Data, 2000, reprinted in 2005.